Circulating plasmin-antiplasmin complexes in acute leukaemia

Area of Science:

• Hematology
• Biochemistry
• Oncology

Background:

• Acute leukaemia frequently involves complex hemostatic abnormalities.
• Fibrinolytic activity, a key component of hemostasis, can be dysregulated in these patients.

Purpose of the Study:

• To investigate the presence of plasma-alpha 2 antiplasmin (P-AP) complexes during heightened fibrinolytic activity in acute leukaemia.
• To correlate P-AP complex detection with conventional laboratory markers of fibrinolysis and clinical manifestations.

Main Methods:

• Studied 30 consecutive acute leukaemia patients throughout their hospital course.
• Monitored for plasma-alpha 2 antiplasmin (P-AP) complexes and other laboratory parameters indicative of fibrinolysis.
• Correlated findings with clinical events such as infection, chemotherapy, and haemorrhage.

Main Results:

• Increased fibrinolytic activity was detected in 63% of patients, often at diagnosis.
• P-AP complexes were found in 37% of patients, typically coinciding with other signs of increased fibrinolysis.
• P-AP complexes were associated with low alpha 2-antiplasmin and plasminogen levels, and major haemorrhagic manifestations at diagnosis.

Conclusions:

• P-AP complexes serve as a marker for increased fibrinolysis in acute leukaemia.
• Their presence is linked to bleeding complications and normalization of coagulation parameters post-chemotherapy.
• Monitoring P-AP complexes may aid in assessing disease activity and treatment response.